A clinical update on the role of carfilzomib in the treatment of relapsed or refractory multiple myeloma

B. Franken, N. W. C. J. van de Donk, J. C. Cloos, S. Zweegman, H. M. Lokhorst

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)330-344
JournalTherapeutic advances in hematology
Issue number6
Publication statusPublished - Dec 2016


  • carfilzomib
  • myeloma
  • proteasome inhibitor
  • refractory
  • relapse

Cite this